Newly Generated Heparanase Knock-Out Mice Unravel Co-Regulation of Heparanase and Matrix Metalloproteinases Authors: Eyal Zcharia, Juan Jia, Xiao Zhang, Lea Baraz, Ulf Lindahl, Tamar Peretz, Israel Vlodavsky, Jin-Ping Li Published: 2009, PLOS ONE DOI: 10.1371/journal.pone.0005181 ABSTRACT Heparanase, a mammalian endo-β-D-glucuronidase, specifically degrades heparan sulfate proteoglycans ubiquitously associated with the cell surface and extracellular matrix. This single gene encoded enzyme is over-expressed in most human cancers, promoting tumor metastasis and angiogenesis. We report that targeted disruption of the murine heparanase gene eliminated heparanase enzymatic activity, resulting in accumulation of long heparan sulfate chains. Unexpectedly, the heparanase knockout ( Hpse -KO) mice were fertile, exhibited a normal life span and did not show prominent pathological alterations. The lack of major abnormalities is attributed to a marked elevation in the expression of matrix metalloproteinases, for example, MMP2 and MMP14 in the Hpse -KO liver and kidney. Co-regulation of heparanase and MMPs was also noted by a marked decrease in MMP (primarily MMP-2,-9 and 14) expression following transfection and over-expression of the heparanase gene in cultured human mammary carcinoma (MDA-MB-231) cells. Immunostaining (kidney tissue) and chromatin immunoprecipitation (ChIP) analysis ( Hpse -KO mouse embryonic fibroblasts) suggest that the newly discovered co-regulation of heparanase and MMPs is mediated by stabilization and transcriptional activity of β-catenin. The lack of heparanase expression and activity was accompanied by alterations in the expression level of MMP family members, primarily MMP-2 and MMP-14. It is conceivable that MMP-2 and MMP-14, which exert some of the effects elicited by heparanase (i.e., over branching of mammary glands, enhanced angiogenic response) can compensate for its absence, in spite of their different enzymatic substrate. Generation of viable Hpse -KO mice lacking significant abnormalities may provide a promising indication for the use of heparanase as a target for drug development. INTRODUCTION Studies on the involvement of extracellular matrix (ECM) molecules in cell attachment, growth and differentiation revealed a central role of heparan sulfate proteoglycans (HSPGs) in embryogenesis, morphogenesis, angiogenesis and epithelial-mesenchymal interactions [1] , [2] , [3] . Heparan sulfate (HS) chains interact with a multitude of proteins and ensure that a wide variety of bioactive molecules (e.g.-growth factors, chemokines, lipoproteins, enzymes) bind to the cell surface and ECM. HSPGs can thus influence a number of normal and pathological processes, among which are tissue repair, neurite outgrowth, inflammation and autoimmunity, tumor growth and metastasis, vasculogenesis and angiogenesis [1] , [2] , [3] , [4] , [5] . The ECM provides an essential physical barrier between cells and tissues, as well as a scaffold for cell growth, migration, differentiation and survival. It undergoes continuous remodeling during development and in certain pathological conditions such as wound healing, inflammation and cancer [6] . Cleavage of HS side chains is therefore expected not only to alter the structural integrity of the ECM, but also to release and modulate the activities of HS-bound biological mediators [4] . Mutational studies in drosophila and targeted disruption of murine genes involved in HS biosynthesis, or encoding HSPG core proteins, have demonstrated a critical role for HSPGs in developmental processes [7] , [8] , [9] . The observed phenotypes vary dramatically in severity, from failure to gastrulate [10] to selective impairment of mast cell function in otherwise seemingly healthy mice [11] . Heparanase is an endo-β-D-glucuronidase capable of cleaving HS side chains at a limited number of sites [12] , [13] , [14] . Heparanase activity has been correlated and causally associated with the metastatic potential of tumor-derived cells, attributed to enhanced cell dissemination as a consequence of HS cleavage and remodeling of the ECM barrier [14] , [15] . Similarly, heparanase activity is implicated in neovascularization, inflammation and autoimmunity, involving migration of vascular endothelial cells and activated cells of the immune system [14] , [15] , [16] . Moreover, heparanase upregulation correlates with increased tumor vascularity and poor post-operative survival of cancer patients [17] , [18] , [19] , [20] . The present study focuses on the generation of heparanase deficient mice by gene targeting. Despite complete lack of heparanase gene expression and enzymatic activity, the mice developed normally, were fertile and did not exhibit apparent anatomical and functional abnormalities, presumably because heparanase deficiency was compensated in most organs (i.e., liver, kidney) by a marked elevation in the expression of matrix metalloproteinase i.e., MMP-9 and MMP-14 family members. This newly discovered association between heparanase and MMPs suggests a combined interdependent control mechanism regulating the basal level of ECM degrading enzymes in cells and tissues. MATERIALS AND METHODS A 15-kb genomic clone containing the 5′ end of the heparanase gene ( Hpse ) was isolated from a bacteriophage mouse (strain 129/Sv) genomic library (Stratagene, Cedar Creek, TX). A 2.5-kb fragment upstream of exon 1 was cloned, as the short homologous arm, into pNT-Lox2 plasmid (kindly provided by Dr. Peter Carmeliet, Department of Molecular and Cellular Medicine, Catholic University, Leuven, Belgium) downstream of the neomycin resistance gene ( neo cassette). A 4.8-kb fragment downstream of exon 1 was cloned upstream of the neo cassette as the long homologous arm of the endogenous gene. The targeting vector construct had a total size of about 14.5-kb. HOMOLOGOUS RECOMBINATION IN ES CELLS AND GENERATION OF HEPARANASE DEFICIENT MICE The targeting vector was linearized by the restriction enzyme Not I and electroporated into R1 embryonic stem (ES) cells. Clones expressing the neo -resistant gene were selected by including G418 (350 µg/ml; Invitrogen, Carlsbad, CA) in the cell culture medium and analyzed for target gene homologous recombination by Southern blot analysis of genomic DNA. The positive clones were injected into C57BL/6 blastocysts, and chimeric male founder mice were crossed with C57BL/6 females. Heterozygous mice were further crossed for 10 generations with C57BL/6J mice to produce Hpse -KO mice on a C57BL/6J background. All animal experiments were conducted in compliance with the Swedish and the Israeli legislation for animal welfare. All the animal experiments were approved by the animal committees of the Hebrew University, Jerusalem Israel (MD-89.49-4) and the Biomedical Center, University of Uppsala, Sweden (C176/2) according to the NIH guidelines. GENOTYPE ANALYSIS The genotype was determined by Southern blot analysis and PCR. Briefly, genomic DNA extracted from ES cells or tail biopsies was digested with either EcoR V or Sca1. The resulting fragments were separated on 0.8% agarose gels and blotted onto a Nylon membrane, followed by hybridization with 32 P-labeled probe #3, as shown in Figure 1A . A. Structure of the 5′ end of the heparanase ( Hpse) gene (top-normal allele), the targeting vector (middle- K/O allele), and the expected size of products obtained by digestion with Sca1 or EcoRv (bottom). The orientation of the neo cassette and the southern blot probes are indicated. B. Southern blot analysis. Genomic DNA was extracted from embryos of the intercross of Hpse +/− heterozygous mice and subjected to Southern blot analysis after digestion with ERv. Wild type ( wt ) embryos exhibited only the normal allele, heterozygous embryos exhibited both the normal and the mutated allele, while Hpse- KO mice exhibited only the shorter, KO allele. Samples were hybridized with the external probe 3, shown in A. C. Heparanase mRNA expression. RNA was extracted from lungs and spleens of wt and Hpse- KO mice and subjected to PCR analysis of heparanase expression using 3 different PCR primer pairs designed to amplify different regions of the Hpse gene, as indicated. Heparanase expression was identified in samples derived from wt but not from Hpse- KO mice. D. Heparanase activity. Blood samples derived from 4 wt and 4 Hpse- KO mice, as well as total cell lysate derived from JAR cells, were incubated (16 h, 37°C, pH 6.2) with sulfate labeled ECM. Labeled degradation products released into the incubation medium were subjected to gel filtration analysis on Sepharose 6B, as described in “ Materials and Methods ”. High heparanase activity was noted only in samples derived from wt mice; no heparanase activity was detected in Hpse- KO samples or JAR cell lysate. E. HS degradation. Liver, kidney and spleen tissue extracts derived from wt and Hpse- KO mice were prepared as described in “ Materials and Methods ” and incubated (18 h, 37°C, pH 5.8) with 3 H-acetyl labeled HS. The reaction mixture was then subjected to gel chromatography on Superose-12. The upper panel shows blank (peak I; control 3 H-acetyl labeled HS substrate) and positive control (control substrate treated with recombinant heparanase; peak II). Incubations of Hpse -KO tissue extracts (black) resulted in the same elution profile as the blank incubation (upper panel), indicating no detectable heparanase activity. In contrast, incubations with wt tissue extracts (purple) resulted in substantial cleavage of the HS substrate, similar to incubation with recombinant heparanase (upper panel). DETECTION OF GENE EXPRESSION Total RNA was isolated from about 100 mg tissue using TRIzol (Invitrogen, Carlsbad, CA), according to the manufacturer's instructions, and quantified by spectrophotometry. After oligo (dT)-primed reverse transcription of 500 ng of total RNA, the resulting single stranded cDNA was amplified using the primers listed in Table 1 . PCR conditions for heparanase were denaturation for 2 min at 94°C followed by 25 cycles of denaturation for 15 seconds at 94°C, annealing for 1 min at 58°C, and extension for 1 minute at 72°C. Aliquots (10 µl) of the amplified products were separated by electrophoresis on a 1.5% agarose gel and visualized by ethidium bromide staining (Hy Labs, Rehovot, Israel). The primers used for PCR are summarized in Table 1 . TABLE: PCR primers. Gene sequence (5′→3′) L-19 S: 5′-ATGCCAACTCTCGTCAACAG-3′ AS: 5′-GCGCTTTCGTGCTTCCTT-3′ Hpse 5′ S: 5′-CGACCGACGACGTGGTAGAC-3′ AS: 5′-GCAACAGCTCCTGGAAGGG-3′ Hpse middle S: 5′-TTTCTGAGCTCTGATGCGCTG-3′ AS: 5′-TGGGCCTTTCACTCTTGACAG-3′ Hpse 3′ S: 5′-ACTTGAAGGTACCGCCTCCG-3′ AS: 5′-GAAGCTCTGGAACTCGGCAA-3′ PREPARATION OF ECM COATED DISHES Bovine corneal endothelial cells were established and cultured as described [21] . For preparation of sulfate-labeled ECM, corneal endothelial cells were cultured in the presence of Na 2 [ 35 S]O 4 (GE Healthcare Bioscience, Uppsala, Sweden) added (25 µCi/mL) on days 1 and 5 after seeding. Seven to 10 days later, the cell monolayer was dissolved and the ECM exposed, as described [21] , [22] . HEPARANASE ACTIVITY Heparanase enzymatic activity was determined in blood samples and tissue extracts derived from heparanase deficient (Hpse -KO) and wild type ( wt ) mice. Serum samples were diluted 1:1 in reaction buffer (20 mM phosphate–citrate buffer pH 6.2, containing 1 mM dithiothreitol, 1 mM CaCl 2 , and 50 mM NaCl) and incubated (16 h, 37°C) with 35 S-labeled ECM, prepared as described above. The incubation medium was centrifuged (20,000×g, 4°C, 1 min), and the supernatant containing 35 S-labeled HS degradation fragments was analyzed by gel filtration on a Sepharose CL-6B column. Fractions (0.2 mL) were collected and the amount of radioactivity in each fraction was counted in a beta scintillation counter. Nearly intact HSPGs were eluted from Sepharose 6B just after the void volume (peak I, Kav<0.2), while HS degradation fragments are eluted towards the V t of the column (peak II, 0.5